Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
6.47
Dollar change
+0.36
Percentage change
5.89
%
IndexRUT P/E- EPS (ttm)-2.46 Insider Own25.48% Shs Outstand84.64M Perf Week15.33%
Market Cap580.06M Forward P/E- EPS next Y-2.79 Insider Trans-0.00% Shs Float63.09M Perf Month0.94%
Income-197.03M PEG- EPS next Q-0.68 Inst Own76.17% Short Float27.07% Perf Quarter15.12%
Sales24.40M P/S23.77 EPS this Y21.22% Inst Trans13.40% Short Ratio11.90 Perf Half Y24.18%
Book/sh6.01 P/B1.08 EPS next Y-13.61% ROA-30.87% Short Interest17.08M Perf Year-48.20%
Cash/sh6.02 P/C1.07 EPS next 5Y- ROE-40.67% 52W Range4.30 - 19.34 Perf YTD-53.59%
Dividend Est.- P/FCF- EPS past 5Y-67.06% ROI-34.60% 52W High-66.55% Beta1.71
Dividend TTM- Quick Ratio13.05 Sales past 5Y126.44% Gross Margin73.07% 52W Low50.29% ATR (14)0.57
Dividend Ex-Date- Current Ratio13.05 EPS Y/Y TTM20.64% Oper. Margin-928.60% RSI (14)57.60 Volatility14.74% 10.08%
Employees255 Debt/Eq0.14 Sales Y/Y TTM219.91% Profit Margin-807.62% Recom1.36 Target Price24.78
Option/ShortYes / Yes LT Debt/Eq0.12 EPS Q/Q18.17% Payout- Rel Volume0.57 Prev Close6.11
Sales Surprise149.99% EPS Surprise13.69% Sales Q/Q120.24% EarningsNov 05 BMO Avg Volume1.43M Price6.47
SMA2013.70% SMA5017.01% SMA200-7.27% Trades Volume824,555 Change5.89%
Date Action Analyst Rating Change Price Target Change
Apr-08-24Initiated H.C. Wainwright Buy $15
Apr-13-23Initiated Canaccord Genuity Buy $29
Feb-01-23Initiated Cantor Fitzgerald Neutral $21
Dec-15-22Initiated Goldman Sell $13
Oct-06-22Initiated Credit Suisse Neutral $48
Aug-25-22Upgrade Stifel Hold → Buy $32 → $56
Jun-17-22Initiated BMO Capital Markets Outperform $48
Feb-18-22Initiated RBC Capital Mkts Outperform $42
Sep-24-21Initiated Stifel Hold $58
Jul-12-21Initiated William Blair Outperform $92
Nov-29-24 04:05PM
Nov-05-24 08:15AM
07:13AM
07:00AM
Nov-01-24 04:26PM
10:00AM Loading…
Oct-28-24 10:00AM
Oct-23-24 10:00AM
Oct-16-24 05:01PM
Oct-11-24 06:15AM
Oct-03-24 04:56AM
Oct-02-24 04:05PM
11:15AM
Sep-20-24 04:40PM
Sep-12-24 01:15AM
Sep-08-24 04:51PM
11:49AM Loading…
11:49AM
Sep-05-24 08:30AM
Sep-03-24 04:05PM
Aug-08-24 10:00AM
08:40AM
07:47AM
07:00AM
Aug-02-24 04:05PM
Jul-08-24 07:07PM
12:30PM
Jul-01-24 04:05PM
Jun-28-24 07:00AM
May-31-24 04:01PM
07:00AM
May-30-24 04:01PM
06:27AM Loading…
May-17-24 06:27AM
May-12-24 04:00PM
May-08-24 01:54PM
08:10AM
07:10AM
07:00AM
May-07-24 07:20AM
07:00AM
May-03-24 04:01PM
Apr-19-24 10:30AM
Apr-06-24 09:50AM
Apr-03-24 01:40PM
Apr-02-24 04:04PM
10:36AM
09:31AM
09:01AM
07:35AM
07:00AM
07:00AM
03:03AM
Mar-28-24 04:51PM
Mar-21-24 04:19PM
Mar-01-24 04:01PM
Feb-27-24 07:02PM
08:03AM
07:30AM
Feb-19-24 04:08PM
Feb-13-24 06:05AM
Feb-12-24 08:30AM
Feb-01-24 06:30AM
Jan-31-24 12:28PM
Jan-17-24 12:04PM
Jan-11-24 04:38PM
Jan-04-24 08:00AM
Jan-02-24 06:30AM
Dec-29-23 12:00PM
09:55AM
Dec-13-23 09:55AM
Dec-06-23 12:31PM
Dec-01-23 04:00PM
Nov-28-23 10:37PM
04:01PM
Nov-27-23 09:55AM
Nov-20-23 04:26PM
Nov-17-23 03:41PM
Nov-16-23 05:41AM
05:20AM
Nov-13-23 07:20PM
04:03PM
02:28PM
12:17PM
12:07PM
08:56AM
Nov-12-23 03:30PM
10:34AM
Nov-09-23 09:55AM
08:00AM
05:57AM
Nov-07-23 07:56AM
06:36AM
06:30AM
Nov-06-23 08:02AM
Nov-01-23 07:06AM
05:40AM
Oct-31-23 07:09PM
04:04PM
06:01AM
05:00AM
Oct-30-23 03:46PM
08:30AM
Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dorval AllisonChief Financial OfficerDec 02 '24Sale5.645553,1305,380Dec 03 04:30 PM
Kathiresan SekarChief Executive OfficerJun 28 '24Option Exercise2.8730,00086,100351,128Jul 02 07:30 AM
Ashe Andrew D.See RemarksMay 14 '24Buy6.2676,000475,760342,509May 15 05:30 PM
Nickerson JoanChief Administrative OfficerApr 02 '24Sale8.241,51412,4758,659Apr 03 05:00 PM